Association of Glucagon-like peptide-1 receptor agonists use with fracture risk in type 2 diabetes: A meta-analysis of randomized controlled trials.

Zhang Y, Chen G, Wang W, Yang D, Zhu D, Jing Y

Bone26 Nov 2024Cited by 27 (Europe PMC)

PMID39603373DOI10.1016/j.bone.2024.117338PepBankPUB-39603373

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. 1 result from people.

01HumanSystematic reviewEfficacy outcome
In reviewed T2D patients, liraglutide was associated with lower fracture risk (RR 0.42; 95% CI 0.21-0.85); its exact subgroup comparator was unstated.
In plain wordsIn reviewed T2D patients, liraglutide was linked to lower fracture risk; the specific subgroup comparison was unstated.
Peptide
Liraglutide
Outcome
DecreaseFracture risk
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Measurements
Fracture relative risk
0.42
liraglutide subgroup; 95% CI 0.21-0.85; exact reference unspecified
Source sentences
Summary
Furthermore, subgroup analyses showed that liraglutide treatment was associated with a significant reduction in fracture risk (RR 0.42; 95 % CI: 0.21-0.85).
3 context sentences(design, population, supporting numbers)
Summary · context
A systematic search based on PubMed, Embase and Web of Science databases was performed to collect relevant literature published until May 2024 on the application of GLP-1 RAs in T2DM patients.
Summary · context
Data were extracted from each study for comparative analysis, and meta-analysis was performed using R software to calculate relative risk (RR) and 95 % confidence intervals (CI) for dichotomous variables.
Summary · context
A total of 44 randomized controlled trials (RCTs) involving 47,823 patients were analyzed.
Report a problemFND-3960337303

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed T2D patients, pooled GLP-1 receptor agonists were associated with lower fracture risk than placebo or other antidiabetic drugs (RR 0.77; 95% CI 0.61-0.96).
In plain wordsIn reviewed T2D patients, pooled GLP-1 drugs were linked to lower fracture risk than placebo or other diabetes drugs.
Peptide
Liraglutide
Outcome
DecreaseFracture risk
Study
n = 47,823
Comparator
Placebo or other anti-diabetic drugs
Outcome group
Bone and joint · Musculoskeletal
Measurements
Fracture relative risk
0.77
pooled GLP-1RAs versus placebo or other antidiabetic drugs; 95% CI 0.61-0.96
Source sentences
Summary
The pooled RR for fractures in patients treated with GLP-1RAs compared with those treated with placebo or other anti-diabetic drugs was 0.77 (95 % CI: 0.61-0.96).
3 context sentences(design, population, supporting numbers)
Summary · context
A systematic search based on PubMed, Embase and Web of Science databases was performed to collect relevant literature published until May 2024 on the application of GLP-1 RAs in T2DM patients.
Summary · context
Data were extracted from each study for comparative analysis, and meta-analysis was performed using R software to calculate relative risk (RR) and 95 % confidence intervals (CI) for dichotomous variables.
Summary · context
A total of 44 randomized controlled trials (RCTs) involving 47,823 patients were analyzed.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3960337301
03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed T2D patients, fracture-risk benefit was reported only for pooled GLP-1RA treatment beyond 78 weeks (RR 0.77; 95% CI 0.61-0.96) versus pooled comparison treatments.
In plain wordsIn reviewed T2D patients, pooled GLP-1 fracture-risk benefit versus comparison treatments was reported only beyond 78 weeks.
Peptide
Liraglutide
Outcome
DecreaseFracture risk after more than 78 weeks
Study
n: not reported in source
Comparator
Placebo or other anti-diabetic drugs
Outcome group
Bone and joint · Musculoskeletal
Measurements
Fracture relative risk
0.77
pooled GLP-1RA treatment >78 weeks; 95% CI 0.61-0.96; placebo or other antidiabetic comparators
Source sentences
Summary
Subgroup analyses showed that the beneficial effect was dependent on the period of treatment with GLP-1 RAs, only treated for >78 weeks were effective in reducing the risk of fractures in patients with T2DM (RR 0.77; 95 % CI: 0.61-0.96).
4 context sentences(design, population, supporting numbers)
Summary · context
The pooled RR for fractures in patients treated with GLP-1RAs compared with those treated with placebo or other anti-diabetic drugs was 0.77 (95 % CI: 0.61-0.96).
Summary · context
A systematic search based on PubMed, Embase and Web of Science databases was performed to collect relevant literature published until May 2024 on the application of GLP-1 RAs in T2DM patients.
Summary · context
Data were extracted from each study for comparative analysis, and meta-analysis was performed using R software to calculate relative risk (RR) and 95 % confidence intervals (CI) for dichotomous variables.
Summary · context
A total of 44 randomized controlled trials (RCTs) involving 47,823 patients were analyzed.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3960337302
04HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In reviewed T2D trials, there were 138 incident fracture cases in pooled GLP-1RA groups and 154 in controls, 292 total; counts were not native liraglutide estimates.
In plain wordsIn reviewed T2D trials, pooled GLP-1 groups recorded 138 fractures and controls 154; these were not liraglutide-specific counts.
Peptide
Liraglutide
Outcome
Not applicableIncident fracture case counts
Study
n: not reported in source
Comparator
Control groups
Outcome group
Bone and joint · Musculoskeletal
Measurements
Incident fracture cases
138 cases
pooled GLP-1RA groups
Incident fracture cases
154 cases
control groups
Total incident fracture cases
292 cases
both study groups
Source sentences
Summary
There were 292 incident fracture cases (138 in GLP-1 RAs group and 154 in control group).
4 context sentences(design, population, supporting numbers)
Summary · context
The pooled RR for fractures in patients treated with GLP-1RAs compared with those treated with placebo or other anti-diabetic drugs was 0.77 (95 % CI: 0.61-0.96).
Summary · context
A systematic search based on PubMed, Embase and Web of Science databases was performed to collect relevant literature published until May 2024 on the application of GLP-1 RAs in T2DM patients.
Summary · context
Data were extracted from each study for comparative analysis, and meta-analysis was performed using R software to calculate relative risk (RR) and 95 % confidence intervals (CI) for dichotomous variables.
Summary · context
A total of 44 randomized controlled trials (RCTs) involving 47,823 patients were analyzed.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3960337304

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.